Insight Resource Library Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: obesity, diabetes, MASH, CKD, IPF and IBD. Filtered (29) Filters Reset all × AMLN DIO-MASH mouse × Echocardiography (ECG) × Glibenclamide × Neuropeptide FF receptor type 2 × Proteomics × Spirometry × TAAR1 agonists × Search × Resource type Data presentation (0) Poster (6) Publication (23) 3D imaging video (0) Webinar (0) Category × Disease model (223) Cardiovascular disease (11) AngII mouse (2) DIO-ApoE-KO mouse (1) DIO-LDLR-KO mouse (4) DIO-PCK9-AAV mouse (1) Isoprenaline-induced cardiomyopathy (1) Cholangiopathy (1) Bile duct ligation (BDL) mouse (1) Mdr2-KO mouse (1) CNS disease (39) Alzheimer's disease models (9) CNS activation (12) Drug distribution (6) Gene expression (1) Gene therapy (1) Parkinson's disease models (6) Diabetes (33) db/db mouse (17) Non-obese diabetic (NOD) mouse (4) ZDF rat (10) Inflammatory bowel disease (3) Acute DSS-IBD mouse (0) Chronic DSS-IBD mouse (3) Idiopathic pulmonary fibrosis (7) BLEO-IPF mouse (4) Chronic BLEO-IPF mouse (2) HFD-BLEO-IPF mouse (0) Kidney disease (33) Acute kidney injury (4) Bilateral ischemia reperfusion injury (bIRI) mouse (1) Unilateral ischemia reperfusion injury (uIRI) mouse (3) Chronic kidney disease (18) Anti-GBM glomerulonephritis mouse (2) Adenine diet-induced (ADI) nephropathy mouse (5) Polycystic kidney disease (PCK) rat (1) Unilateral ureteral obstruction (UUO) mouse (4) 5/6 nephrectomy (Nx) rat (3) Diabetic kidney disease (17) db/db-UNx mouse (1) ReninAAV UNx db/db mouse (11) ZSF-1 rat (0) Knock-out mouse models (8) Metabolic dysfunction-associated steatohepatitis (76) GAN DIO-MASH mouse (30) GAN DIO-MASH-HCC mouse (8) GAN ob/ob-MASH mouse (5) CDAA-HFD mouse (9) CDAA-HFD rat (10) AMLN DIO-MASH mouse (18) AMLN ob/ob-MASH mouse (13) Obesity (52) Bariatric surgery (10) DIO mouse (23) DIO rat (14) ob/ob mouse (8) Therapeutic Area (242) Alzheimer's disease (13) Alcoholic steatohepatitis (2) Cardiovascular disease (10) Chronic kidney disease (28) Cholangiopathy (1) Diabetes (55) Diabetic cardiomyopathy (2) Diabetic kidney disease (18) Hepatocellular carcinoma (6) Idiopathic pulmonary fibrosis (7) Inflammatory bowel disease (3) Metabolic dysfunction-associated steatohepatitis (84) Obesity (81) Parkinson's disease (8) Target (149) Alpha-synuclein (1) Autotaxin (1) Beta amyloid (4) Acetyl-CoA carboxylase (2) Amylin receptor (4) Angiotensin converting enzyme (ACE) (5) AMPK (1) ASBT (2) CB1 receptor (5) CCK receptor (4) D2 receptor (3) DPP-IV (2) Fatty acid synthase (1) FGF receptor-1 (3) FXR (12) GCC receptor (1) GFRAL (1) Ghrelin receptor (3) GIP receptor (5) GLP-1 receptor (73) GLP-2 receptor (5) Glucagon receptor (5) GPR119 (0) GPR120 (1) G-protein coupled receptor 10 (GPR10) (1) HSD17b13 (1) 5-HT2C receptor (3) IL-1beta receptor (1) Insulin receptor (2) mARC1 (1) MC4 receptor (4) Monoamine transporter (2) Leptin receptor (1) Neuropeptide FF receptor type 2 (1) Neurotensin receptor (1) Nicotinic acetylcholine receptor (1) NPY receptor (2) NMU receptor (2) Paraoxonase-2 (1) PCSK9 (1) PICK1 (1) PPAR (22) PSD-95 (1) Renin–angiotensin system (3) Secretin receptor (1) SGLT-2 (5) TAAR1 (1) TGF-beta (7) TGR5 (2) THR-ß receptor (5) Y2 receptor (3) Compound (146) Aducanumab biosimilar (4) Adeno-associated virus (AAV)-mediated gene therapy (1) A3907 (2) Adrenomedullin (2) Alk5 inhibitor (6) ALT-801 (1) Amylin (3) Amylin receptor agonist (1) BLD-0409 (1) Bromocriptine (2) CHS-131 (1) Captopril (1) Cilofexor (1) Cotadutide (1) DA-1241 (1) Dapagliflozin (2) Dietary intervention (4) Exenatide (9) Elafibranor (9) Empagliflozin (4) Exendin-4 analogues (3) FGF21 (3) Firsocostat (2) GDF15 analogues (1) Ghrelin (1) GIP receptor agonist (1) GIPRA (1) GIP receptor antagonist (1) Glibenclamide (1) GLP-1 (5) GLP-1 receptor agonist (5) GLP-2 (1) Glucagon receptor agonist (1) Glucose-dependent insulinotropic polypeptide (GIP) (1) Guanylin (1) GUB06-046 (1) GUB08-248 (1) GUB09-123 (1) GUB09-145 (2) GUB08251 (1) GUB021794 (1) GUBamy (1) GS-834356 (1) HSD17b13 inhibitor (1) HSG4113 (1) Icosabutate (1) ID166 (0) Insulin (1) INT-767 (4) INT-787 (0) Lanifibranor (9) LEAP-2 (2) Leptin (1) Linagliptin (5) Liraglutide (30) Lisinopril (5) Lorcaserin (3) MEDI0382 (1) mPD95 (1) Neuromedin U (2) Neurotensin (1) Neurturin (1) Nicotine (1) Obeticholic acid (10) Oxyntomodulin (1) PYY3-36 (4) Prolactin-releasing peptide (1) Resmetirom (6) Rimonabant (4) Rosiglitazone (2) S961 (1) Salmon calcitonin (1) SEFA-1024 (1) Seladelpar (2) Semaglutide (31) SER140 (1) Setmelanotide (3) Sibutramine (4) TAAR1 agonists (1) Taspoglutide (1) Teduglutide (2) Tirzepatide (1) TVB-3664 (1) UCCB01-147 (1) Uroguanylin (1) Vutiglabridin (1) Y2 receptor agonist (1) ZP3022 (3) Method/Endpoint (265) 3D imaging (57) Adeno-associated virus (AAV)-mediated gene delivery (14) Atherosclerotic plaques (3) Beta-cell mass (12) Blood pressure (1) Body composition (11) Body weight (123) Blood biochemistry (84) Bariatric surgery (12) Bioinformatics (105) c-Fos activation (19) Clinical trial (2) Conditioned taste aversion test (1) Drug discovery (25) Drug distribution (11) Energy expenditure monitoring (4) Echocardiography (ECG) (3) Flow cytometry (1) Gut biopsy (6) Glomerular filtration rate (GFR) (8) Gastric emptying (3) Gut morphometry (12) Glucose-stimulated insulin secretion (GSIS) (1) Histopathology score (79) Heart morphometry (5) Intraperitoneal glucose tolerance test (IPGTT) (7) Image analysis (150) Immunohistochemistry (IHC) (145) In situ hybridization (ISH) (14) Insulin tolerance test (ITT) (2) Kidney biopsy (2) Kidney morphometry (24) Lung functional test (5) Light sheet fluorescence microscopy (LSFM) (60) Liver biopsy (67) Liver morphometry (65) Lung biochemistry (4) Laser-capture microdissection (LCM) (9) Magnetic resonance imaging (MRI) (2) Microbiomics (5) Micro-computed tomography (micro-CT) (1) Neurobehavior (6) Next-generation sequencing (49) Nephrectomy (14) Oral glucose tolerance test (OGTT) (20) Pancreatectomy (1) Peptide chemistry (14) Pharmacokinetics (9) Proteomics (1) qPCR (1) Real-time food intake/activity analysis (32) Receptor binding (3) Roux-en-Y gastric bypass (RYGB) (8) RNA sequencing (84) Single-cell RNA sequencing (3) Single-nucleus RNA sequencing (6) siRNA (1) StreaMLine (1) Surgery (12) Spirometry (5) Stereology (29) Stereotaxic injection (2) Ultrasound imaging (1) Urine biochemistry (12) Vasculature (2) Vertical sleeve gastrectomy (1) Western Blotting (1) Whole-body plethysmography (4) Whole-brain in situ hybridization (4) Species (219) Hamster (1) Human (29) Mouse (177) Minipig (2) Non-human primate (3) Pig (3) Rat (34) Show (29) Cancel Sort result Default sorting By title: alphabetical By title: reverse By date: oldest first By date: newest first Reset all × AMLN DIO-MASH mouse × Echocardiography (ECG) × Glibenclamide × Neuropeptide FF receptor type 2 × Proteomics × Spirometry × TAAR1 agonists × 29 resource library items found PublicationAn unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) PosterRepetitive intratracheal bleomycin induces persistent progressive lung fibrosis in a spirometry-confirmed mouse model of IPF PosterReproducible lung protective effects of a TGFβR1/ALK5 inhibitor in the bleomycin-induced and spirometry-confirmed mouse model of IPF PublicationParaoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis PosterReproducibility and therapeutic effects of ALK5i on pulmonary function and fibrosis in a bleomycin-induced and spirometry-confirmed mouse model of IPF PublicationTAAR1 Agonists Improve Glycemic Control, Reduce Body Weight and Modulate Neurocircuits Governing Energy Balance and Feeding PublicationEvaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients PosterWhole body plethysmography-enabled stratification of lung functional deficits in a bleomycin-induced and spirometry-confirmed mouse model of IPF PosterA chronic angiotensin II infusion mouse model of hypertension-induced cardiac fibrosis PosterLung disease progression in a bleomycin-induced and spirometry-confirmed mouse model of IPF PublicationFASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models PublicationEffects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis PublicationLipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect PublicationEmpagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH PublicationElafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis PublicationEffect of captopril on post-infarction remodelling visualized by light sheet microscopy and echocardiography PublicationActivation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis PublicationRat pancreatectomy combined with isoprenaline or uninephrectomy as models of diabetic cardiomyopathy or nephropathy PublicationThe selective peroxisome proliferator‐activated receptor gamma modulator CHS‐131 improves liver histopathology and metabolism in a mouse model of obesity and nonalcoholic steatohepatitis PublicationResolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis PublicationIncretin combination therapy for the treatment of non-alcoholic steatohepatitis PublicationMulti-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis PublicationMastiha (Pistacia Lentiscus) improves gut microbiota diversity, hepatic steatosis and disease activity in a biopsy-confirmed mouse model of advanced non-alcoholic steatohepatitis and fibrosis PublicationAnimal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development Load More For further information Contact us Gubra Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650